



(51) International Patent Classification:

A61P 35/00 (2006.01) C12N 15/63 (2006.01)
C12N 15/86 (2006.01) C12N 9/22 (2006.01)
A61P 35/02 (2006.01)

(21) International Application Number:

PCT/US2022/071958

(22) International Filing Date:

27 April 2022 (27.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/181,583 29 April 2021 (29.04.2021) US

(71) Applicant: MAXCYTE, INC. [US/US]; 22 Firstfield Road, suite 110, Gaithersburg, Maryland 20878 (US).

(72) Inventors: ACHARYA, Diwash; c/o MaxCyte, Inc., 22 Firstfield Road, Suite 110, Gaithersburg, Maryland 20878 (US). BRADY, James; c/o MaxCyte, Inc., 22 Firstfield Road, Suite 110, Gaithersburg, Maryland 20878 (US).

(74) Agent: EDDY, Sarah; 98 San Jacinto Boulevard, suite 1100, Austin, Texas 78701-4255 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: SEQUENTIAL ELECTROPORATION METHODS




FIG. 35

(57) Abstract: Aspects of the disclosure are directed to a technique for sequential electroporation that provides for a delivery of multiple electrical pulses separated in time to cells, cell particles, lipid vesicles, liposomes, or to increase efficiency of entry of one or more agents of interest into cells, cell particles, lipid vesicles, liposomes, tissues, or derivatives thereof, and to minimize damage by electrical arc or heat shock; increase loading efficiency of an agent of interest; and maintain viability of the cells, cell particles, lipid vesicles, or tissues and the ability of the cells, cell particles, lipid vesicles, liposomes, or tissues to produce a clinical effect.

[Continued on next page]



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*